

## NURSING CLINICAL STANDARD

**COVID -19 VACCINATION: CARE OF IN-PATIENTS RECEIVING**

**PURPOSE:** To outline the responsibilities of the licensed nurse in screening the need for and administration of the COVID -19 vaccination.

**SUPPORTIVE DATA:** The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the following vaccinations to prevent COVID-19:

- Pfizer -BioNTech: <http://labeling.pfizer.com/ShowLabeling.aspx?id=14471>
- Moderna: <https://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf>
- Janssen (Johnson & Johnson): <https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf>

Vaccines are NOT interchangeable.

Vaccines will be provided by pharmacy based on inventory.

Screening should be completed during admission or if unable, any time prior to discharge

Licensed nurses can administer vaccines to in-patients who meet the criteria and who do not have any contraindications.

Licensed nurses will consult with a provider as needed for any questions or concerns.

The deltoid is the current acceptable intramuscular injection site. Other injection sites are **NOT** acceptable at this time.

**INITIAL ASSESSMENT:**

1. Screen patients for need via the Immunization Forecaster for the COVID-19 vaccine upon admission, transfer to unit or discharge until completed
2. Open and complete the ORCHID ad-hoc form COVID-19 Vaccine Screen (see addendum for COVID-19 Vaccine Screening Job Aid).
3. Obtain the patient's approval to be vaccinated if eligible (NOTE: No written consent is needed).
  - Parental/guardian must provide approval to vaccinate for minors under 18 years old.
  - Emancipated minors may provide their own approval to receive vaccination.

**ONGOING ASSESSMENT:**

4. Assess periodically for the need of the COVID-19 vaccine during hospitalization until vaccine is administered.

**ORDERING COVID-19  
VACCINE:**

5. Place the appropriate vaccine order based on patient eligibility in the electronic health record (EHR)
  - COVID-19 vaccine will be ordered using “No Co-Sign Required (per protocol)” communication type in the ordering provider window.

**ADMINISTRATION OF  
INITIAL COVID – 19  
VACCINE:**

6. Administer the COVID-19 vaccine intramuscularly prior to discharge as indicated.
  - Observe hand hygiene and other aseptic techniques when administering the vaccine
  - Administer COVID-19 vaccine intramuscularly in either the left or right deltoid muscle as indicated
  - Vaccinate patients while they are seated or lying down to prevent potential injury.
  - Observe for any signs of an allergic reaction to the vaccine:
    - 15 minutes post injection.
    - At least 30 minutes if patient has a history of allergic reactions after any vaccine administration.
7. Prepare for management of a medical emergency related to the administration of vaccine, as necessary.

**SCHEDULING OR  
THE  
ADMINISTRATION OF  
2ND COVID – 19  
VACCINE DOSE:**

8. If a second dose is required, schedule the patient within the recommended time frame to receive the second dose of the same vaccine (same manufacturer).
9. If returning for the second dose, verify if and when the first dose was received in the EHR or on the patient’s COVID-19 Vaccination card.
10. Administer the second dose as indicated following the same vaccination procedure as the first dose.

**REPORTABLE  
CONDITIONS:**

11. Report all adverse events following the administration of COVID-19 vaccine as follows:
  - Notify the provider and document signs, symptoms, treatment and outcome in the EHR.
  - In Safety Intelligence.
  - Pharmacy completes Vaccine Adverse Event Reporting.

**PATIENT/FAMILY  
TEACHING:**

13. Provide all patients and their caregivers with a copy of the most current federal CDC COVID-19 Vaccine Emergency Use Authorization (EUA) Fact Sheets accessible through VIS or the following links:
  - Pfizer BioNTech COVID-19 Vaccine EUA Fact Sheet for Recipients: <https://www.cvdvaccine.com/>
  - Moderna COVID-19 Vaccine EUA Fact Sheet for Recipients: <http://www.modernatx.com/covid19vaccine-eua>
  - Janssen (Johnson & Johnson) COVID -19 Vaccine EUA Fact Sheet for Recipients: <http://www.janssencovid19vaccine.com/>
14. Inform the patient and complete a referral for second dose or any follow-up visit for additional COVID-19 vaccination.
15. Provide information on CDC's v-safe program if the patient would like to report side-effects to the CDC. Enroll through link below:
  - <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html>

**DOCUMENTATION:**

16. Document in accordance with documentation standards
  - Administration of COVID-19 vaccine in the medication administration records (MAR) and complete all the required fields.
  - Document notification to the provider of patient refusal or contraindication in the Provider Notification section.
17. Provide COVID-19 Vaccination Record Card as documentation for first and second dose.

Initial date approved: 06/21	Reviewed and Approved by: Professional Practice Committee Nurse Executive Council Attending Staff Association Executive Committee	Revision Date:
---------------------------------	--	----------------

**REFERENCES:**

- Center for Disease Control and Prevention (2021). <https://www2.cdc.gov/vaccines/ed/covid19>
- Janssen (Johnson & Johnson) COVID -19 Vaccine (2021). <http://www.janssencovid19vaccine.com/>
- Moderna COVID-19 Vaccine (2021). <http://www.modernatx.com/covid19vaccine-eua>
- Pfizer BioNTech COVID-19 Vaccine (2021). <http://www.cvdvaccine.com>